A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease

Part of paid clinical trials in Miami, Florida.

Sponsor
Krystal Biotech, Inc.
Study ID
NCT07717346
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • KB111 — BIOLOGICAL
    KB111 is a replication-defective, non-integrating herpes simplex virus (HSV-1)-based vector encoding functional, full-length human ATP2C1 protein combined with a gel for topical application.

Study Details

An open-label study to evaluate the safety and efficacy of KB111 in pediatric and adult subjects with Hailey-Hailey Disease

Key Dates

First listed
Jul 21, 2026
Start date
May 6, 2026
Status verified
Jul 2026
Primary completion
Nov 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
7 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: KB111
    KB111

Primary Outcome Measure

To evaluate the safety and tolerability of KB111 [ Time Frame: 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Pediatric Skin ResearchMiamiFlorida33156
Jean Marco Varanese
+1 786-585-5774

Find similar trials in Miami, FL

By research site
Pediatric Skin Research· Miami, FL

Related Studies